← Back to patent-cliff list
THR-149
Tier C — Watch / tradeTHR-149
Thrombogenics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KLKB1
Indications (approved)：Diabetes, Diabetic macular oedema, Diabetic retinopathy
Regional status
US
Phase II
2020-07-31
EU
Phase II
2020-07-31
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of THR-149?
Approved indications include: Diabetes, Diabetic macular oedema, Diabetic retinopathy.
When does the THR-149 patent expire?
No public expiry year is available for THR-149 yet; this page updates once verified.
How do I get a quote for THR-149 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06